Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
5.92
-0.12 (-1.99%)
Feb 5, 2026, 11:56 AM EST - Market open
Annexon Employees
Annexon had 99 employees as of September 30, 2025. The number of employees increased by 15 or 17.86% compared to the same quarter last year.
Employees
99
Change
15
Growth
17.86%
Revenue / Employee
n/a
Profits / Employee
-$2,109,909
Market Cap
882.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 99 | 15 | 17.86% |
| Jun 30, 2025 | 103 | 32 | 45.07% |
| Mar 31, 2025 | 106 | 36 | 51.43% |
| Dec 31, 2024 | 100 | 29 | 40.85% |
| Sep 30, 2024 | 84 | 8 | 10.53% |
| Jun 30, 2024 | 71 | -6 | -7.79% |
| Mar 31, 2024 | 70 | -10 | -12.50% |
| Dec 31, 2023 | 71 | -9 | -11.25% |
| Sep 30, 2023 | 76 | -7 | -8.43% |
| Jun 30, 2023 | 77 | 2 | 2.67% |
| Mar 31, 2023 | 80 | 17 | 26.98% |
| Dec 31, 2022 | 80 | 19 | 31.15% |
| Sep 30, 2022 | 83 | 21 | 33.87% |
| Jun 30, 2022 | 75 | 18 | 31.58% |
| Mar 31, 2022 | 63 | 15 | 31.25% |
| Dec 31, 2021 | 61 | 13 | 27.08% |
| Sep 30, 2021 | 62 | 24 | 63.16% |
| Jun 30, 2021 | 57 | 27 | 90.00% |
| Mar 31, 2021 | 48 | 18 | 60.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UroGen Pharma | 287 |
| Geron | 229 |
| ARS Pharmaceuticals | 167 |
| CytomX Therapeutics | 121 |
| Theravance Biopharma | 97 |
| Ventyx Biosciences | 83 |
| ArriVent BioPharma | 52 |
| GH Research | 50 |
ANNX News
- 12 days ago - Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases - Seeking Alpha
- 19 days ago - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 24 days ago - Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - GlobeNewsWire
- 4 weeks ago - Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - GlobeNewsWire
- 4 weeks ago - Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy - Seeking Alpha